ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Outsourcing

Lonza adds gene-editing service with CRISPR license

by Rick Mullin
January 7, 2019 | APPEARED IN VOLUME 97, ISSUE 1

Lonza has licensed CRISPR-Cas9 gene-editing technology from ERS Genomics for use in its new cell biology research division. The drug services firm is adding gene editing to improve the development of cell lines, according to Sarah Holland, head of licensing for Lonza’s biologics business. “If you are going to create and improve cell lines, you really need effective modern tools, and one of those is CRISPR-Cas9,” Holland says. The new research section plans to license another gene-editing technology in 2019, she says.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment